Lv61
1653 积分 2021-08-11 加入
Updated treatment recommendations for systemic treatment: from the ESMO Metastatic Breast Cancer Living Guideline†
9天前
已完结
Clinical and Biomarker Findings of Neoadjuvant Pembrolizumab and Carboplatin Plus Docetaxel in Triple-Negative Breast Cancer
14天前
已完结
Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple‐negative, early‐stage breast cancer (NeoCART): Results from a multicenter, randomized controlled, open‐label phase II trial
14天前
已完结
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer
17天前
已完结
Pembrolizumab for Early Triple-Negative Breast Cancer
17天前
已完结
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
17天前
已完结
Different dosage forms of GnRHa with endocrine therapy in premenopausal hormone Receptor-Positive breast cancer
18天前
已完结
Incomplete ovarian function suppression in premenopausal breast cancer patients treated with gonadotropin-releasing hormone agonists
18天前
已完结
Efficacy and safety of neoadjuvant SHR-A1811 with or without pyrotinib in women with locally advanced or early HER2-positive breast cancer: a randomized, open-label, phase 2 trial
1个月前
已完结
Attrition in the First Three Therapy Lines in Patients with Advanced Breast Cancer in the German Real-World PRAEGNANT Registry
1个月前
已完结
皖公网安备34019202002308
